Close Menu

Biodesix

Researchers affiliated with Biodesix have completed a study indicating that the company's Veristrat test for identifying non-small cell lung cancer patients likely to respond to tyrosine kinase inhibitor treatment plays a significant role in guiding physician decisions.

Biodesix said this week that data from an analysis of serum and plasma samples from a Phase II non-small cell lung cancer study demonstrate that its Veristrat test is able to identify patients likely to benefit when treated with erlotinib – marketed by Roche as Tarceva – and erlo

NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.

NEW YORK (GenomeWeb News) – Pacific Biosciences has appointed Jonas Korlach to chief scientific officer, a position previously held by Eric Schadt, who will remain a key scientific advisor to the company.

Quanterix announced this week it has appointed Paul Chapman as its new president and CEO, replacing Martin Madaus, who will continue at the company as executive chairman.

Biodesix this week presented data indicating that a proteomic signature identified using the company's ProTS mass spec-based system can identify pancreatic cancer patients likely to respond to treatment with GlobeImmune's GI-4000 therapy.

Biodesix last week presented results from a combined analysis of two Phase II trials using its Veristrat lung cancer companion diagnostic.

By Adam Bonislawski
Biodesix said this week that it is collaborating with pharma firm Kadmon on a 620-patient Phase III clinical trial of that company's reversible tyrosine kinase inhibitor KD019.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Gen-Probe disclosed in its annual 2011 earnings document that it has lost almost $41 million in its investment in Pacific Biosciences as of the end of 2011.

Pages

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.